Survival analysis of young adults from a Brazilian cohort of non-small cell lung cancer patients

Imagem de Miniatura
Arquivos
art_NICOLAU_Survival_analysis_of_young_adults_from_a_Brazilian_2021.PDF (1.23 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CANCER INTELLIGENCE LTD
Autores
LUIZAGA, Carolina Terra de Moraes
RIBEIRO, Karina Braga
Citação
ECANCERMEDICALSCIENCE, v.15, article ID 1279, 15p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: The influence of age at diagnosis in non-small cell lung cancer (NSCLC) prognosis is unclear. Objectives: To compare in a Brazilian cohort of NSCLC patients of different age groups: 1) The overall survival; 2) Clinical features and treatment options. Methods: This is a retrospective cohort study using a hospital-based registry, for NSCLC patients registered in years 2000-2009. Patients were grouped into three age groups: Young adults (YA: < 40 years), middle-aged (MA: 40-64 years) and elderly (E: >= 65 years). Kaplan-Meier was used to estimate overall survival and Cox regression for hazard ratios (HRs) and 95% confidence intervals. Results: 17,422 NSCLC patients were included: 370 YA (2.1%), 8,697 MA (49.9%) and 8,355 E (48.0%). Compared with older age groups, the YA group had a higher proportion of females, patients diagnosed with adenocarcinoma and metastatic disease (63.2%). Overall survival was longer in YA in the entire cohort and in all clinical stages (CSs) (p < 0.001). For YA, higher education level was a good prognosis factor (compared with illiterate and incomplete elementary); advanced or metastatic disease (compared with early-stage disease) and treatment based in radiotherapy or chemotherapy (CT) (without surgery), compared with treatment combinations with surgery, were poor prognostic factors. Young men (but not women) had lower HR of death compared with older groups; YA had lower HR of death in all CSs compared with patients from older groups. A higher percentage of YA were treated with surgery or CT in early-stage disease compared with older groups. Besides that, YA and MA patients treated with surgery or CT had a better prognosis than elderlies. Conclusions: In this Brazilian cohort of NSCLC patients, most young individuals were diagnosed with metastatic disease. YA presented longer survival than older age groups in all CSs, but mainly in CS I/II and III, where some patients may achieve long remissions or cure.
Palavras-chave
lung carcinoma, non-small cell lung cancer, young adult, survival, clinical features
URI
https://observatorio.fm.usp.br/handle/OPI/42181
Referências
  1. Ak G, 2007, LUNG, V185, P279, DOI 10.1007/s00408-007-9021-2
  2. Albano JD, 2007, JNCI-J NATL CANCER I, V99, P1384, DOI 10.1093/jnci/djm127
  3. [Anonymous], 2015, WHY SAO PAULO
  4. [Anonymous], 2020, DIRETRIZES ESTRATEGI
  5. [Anonymous], 2020, UNIDADES HABILITADAS
  6. [Anonymous], 2013, SAO PAULO ESTADO COM
  7. [Anonymous], 2020, ESTIMATIVA INCIDENCI
  8. Araujo LH, 2018, J BRAS PNEUMOL, V44, P55, DOI [10.1590/s1806-37562017000000135, 10.1590/S1806-37562017000000135]
  9. Arnold BN, 2016, J THORAC ONCOL, V11, P1121, DOI 10.1016/j.jtho.2016.03.023
  10. Bleyer A, 2008, NAT REV CANCER, V8, P288, DOI 10.1038/nrc2349
  11. Cancer Research UK, 2020, CANC STAT REP UK
  12. Costa GJ, 2018, LUNG CANCER, V125, P77, DOI 10.1016/j.lungcan.2018.09.005
  13. Cronemberger E, 2020, NSCLC CLIN, V75, P1980, DOI [10.6061/clinics/2020/e1777, DOI 10.6061/CLINICS/2020/E1777]
  14. Fang S, 2014, DRUG DES DEV THER, V8, P1595, DOI 10.2147/DDDT.S69690
  15. Franceschini JP, 2017, J BRAS PNEUMOL, V43, P431, DOI [10.1590/S1806-37562016000000298, 10.1590/s1806-37562016000000298]
  16. Handforth C, 2015, ANN ONCOL, V26, P1091, DOI 10.1093/annonc/mdu540
  17. INCA, OBS POL NAC CONTR TO
  18. Jiang W, 2012, CHINESE MED J-PEKING, V125, P72, DOI 10.3760/cma.j.issn.0366-6999.2012.01.014
  19. Mauri D, 2006, ANTICANCER RES, V26, P3175
  20. Radzikowska E, 2001, LUNG CANCER, V33, P203, DOI 10.1016/S0169-5002(01)00199-4
  21. Ramalingam S, 1998, J CLIN ONCOL, V16, P651, DOI 10.1200/JCO.1998.16.2.651
  22. Ribeiro K, 2015, INT J EPIDEMIOL, V44, P3
  23. Rich AL, 2015, QJM-INT J MED, V108, P891, DOI 10.1093/qjmed/hcv052
  24. Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
  25. Subramanian J, 2010, J THORAC ONCOL, V5, P23, DOI 10.1097/JTO.0b013e3181c41e8d
  26. Suidan AM, 2019, J GLOB ONCOL, V5, P1, DOI 10.1200/JGO.18.00216
  27. Tian DL, 2003, LUNG CANCER-J IASLC, V42, P215, DOI 10.1016/S0169-5002(03)00286-1
  28. Tominaga K, 1999, JPN J CANCER RES, V90, P490, DOI 10.1111/j.1349-7006.1999.tb00774.x
  29. United Nations Department of Economic and Social Affairs Population Division, 2019, WORLD POP AG 2019 HI
  30. Cormedi MCV, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e656s
  31. Ye T, 2014, J THORAC DIS, V6, P1396, DOI 10.3978/j.issn.2072-1439.2014.08.50

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/38
Carregar mais